Public trial registry of the CCC-Munich

Trial AMLSG 28-18

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
AMLSG 28-18
World
Full title
:

A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by oneyear maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy

World
NCT number
:
World
Responsible organization
:
3. Med 3. Med Ismaninger Str. 22 81675 München Germany
Indications
Classification Code Description
- Bloodcancer (leukemia, lymphoma)
- - Other trials
Trial design
World
Phase
:
III
Status
World
Status
:
Recruitment active
Votes
Initiiation & lock
World
Date of lock (planned / actual)
:
Unknown / Unknown
Therapy
World
Therapy line
:
1
World
Therapy
:

Chemo,Zielgerichtet

Participants
Function Prename Surname Organization
World Responsible contact Katharina Götze 3. Med 3. Med Ismaninger Str. 22 81675 München Germany Magnifier